Chemical structural characteristics and drug development background of eflornithine (IWILFIN)

Eflornithine (IWILFIN) is a new anti-tumor small molecule drug, which is a pyrimidine analogue and inhibits cancer cells by interfering with nucleic acid metabolism. Its chemical structure is characterized by retaining the pyrimidine core skeleton while introducing fluorine atoms and modifying groups at specific positions. This modification not only enhances the binding affinity of the drug to the target, but also improves in vivo stability and bioavailability. The introduction of fluorine atoms can also increase the electron density of the molecule, making it more resistant to enzyme metabolism, thus extending the half-life of the drug in the body and improving the therapeutic effect.

From a drug research and development background, the research and development of eflornithine originated from the need for improvement of classic pyrimidine anti-metabolite drugs. Traditional pyrimidine drugs such as fluorouracil and capecitabine have achieved certain clinical efficacy, but they have the disadvantages of metabolic instability, strong side effects and the development of drug resistance. Through a molecular design strategy, the research team introduced fluorine atoms and specific side chains into the core structure and successfully developed eflornithine, which not only maintained the inhibitory effect on the synthesis of DNA and RNA, but also improved the pharmacokinetic properties.

Optimization of the chemical structure not only improves the anti-tumor activity of the drug, but also improves selectivity and safety. Eflornithine can preferentially act on rapidly proliferating tumor cells and has relatively low toxicity to normal cells. This structural advantage allows eflornithine to show potential efficacy in the face of a variety of refractory tumors (such as colorectal cancer and pancreatic cancer), and provides new possibilities for combination chemotherapy or targeted therapy.

In general, the research and development background of eflornithine (IWILFIN) reflects the combination of modern medicinal chemistry and clinical needs: solving the limitations of traditional pyrimidine drugs through structural optimization, while taking into account anti-tumor activity and in vivo stability. Its unique chemical structure and improved pharmacokinetic properties provide a useful reference for the development of a new generation of anti-tumor drugs, and also bring more treatment options and hope to clinical patients.

Reference link:https://www.drugs.com